跳至主要内容
临床试验/NCT00370747
NCT00370747已完成2 期

Efficacy and Safety of Ecabet Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Bausch & Lomb Incorporated0 个研究点目标入组 162 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
162
主要终点
Ocular signs and Symptoms

研究概览

简要总结

The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male/female at least 18 years of age
  • Agree to avoid disallowed medications
  • Have a diagnosis of dry eye

排除标准

  • Have chronic systemic inflammation
  • Have active seasonal ocular allergies

研究组 & 干预措施

Ecabet

Experimental

Ophthalmic solution in the Study eye four times daily for 90 days.

干预措施: Ecabet (Drug)

Placebo

Placebo Comparator

Ophthalmic solution in the Study eye four times daily for 90 days.

干预措施: Placebo (Drug)

结局指标

主要结局

Ocular signs and Symptoms

时间窗: 90 days

ocular signs, including corneal and conjunctival staining, tear film breakup time and blink rate, and ocular symptoms, including burning or stinging, itchiness or scratchiness, grittiness or sandiness, foreign body sensation, haziness or blurriness, photophobia, photopsia, and eye discomfort

次要结局

  • Ocular Surface Disease Index (OSDI)(90 days)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验